3-Methyladenine (3-MA)

Catalog No.S2767

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

3-Methyladenine (3-MA) Chemical Structure

3-Methyladenine (3-MA) Chemical Structure
Molecular Weight: 149.15

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

3-Methyladenine (3-MA) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area

Product Description

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Targets Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
IC50 25 μM 60 μM
In vitro The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
95DNGnCcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzFN41OMYOybC=>NIPubmhFVVORM{fCTZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN?MVqyOVcyPjV4MR?=
A549 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PlW|NuVQ>?MnLSNog>NVqzW3gxTE2VTx?=MYPy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1EMnu4NlU4OTZ3NkG=
95DNWrLc2QxSXCxcITvd4l{KEG|c3H5NWH3V4h{PW2PNHWzRnIzcA>?NFPTXnNFVVORMmLZbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSqNFu2T4EzPTdzNkW2NS=>
A549 NVfOZ5E{SXCxcITvd4l{KEG|c3H5MVS1cW0>NFfTXpMzcA>?NYnQUVhvTE2VTx?=NVjE[IFqcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToNVGxeJlCOjV5MU[1OlE>
NBL-W-S NGXq[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVGxcW0>NHSxcWM3cA>?NF\zO4dmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5Mo\tNlU{OjN{MkK=
NBL-W-S NYjDO2Q4SXCxcITvd4l{KEG|c3H5NWfSN4JjOW2PM3r1RlZpNWTzZnRIcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=>M3WyUVI2OzJ|MkKy
A2780cp M1rmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvxR|QydU1?M4DoW|FpMYXpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NHj0e2IzPTN{Mk[5OC=>
A549 M3zve2Z2dmO2aX;uJGF{e2G7NHPmWII2dU1?NXHRTos2Omh?NUO5NoZTe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlKM1fQN|I2Ojh3NkK4
H157MnjmSpVv[3Srb36gRZN{[Xl?NIPUZ2Y2dU1?NV;nTYUzOmh?M4PR[ZN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=>MXWyOVI5PTZ{OB?=
MDRMnX2RZBweHSxc3nzJGF{e2G7MmTVNVBuVQ>?NEfYR5I3cA>?NGLLTJB{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?=M1zzNFI2ODF7N{Cx
HT-29 NWLBOWxySXCxcITvd4l{KEG|c3H5NG\INoEydU1?MXu0PIg>MV\EUXNQMkf2[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M>MXOyOFg1OjF3OB?=
Microglia M3fjRmFxd3C2b4Ppd{BCe3OjeR?=NXXHPFhUPW2PNHHNd5MzPGh?NVjTdW5t\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRpMWeyOFgyQDZyMR?=
A2780cpNGnxXVNCeG:ydH;zbZMhSXO|YYm=MViyMlVuVQ>?M3izXVFpNVLZ[Gtk\GSKMl:=M2P3doVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg>NXWzSW1XOjR6MUe5OFY>
HepG2NGLnTlRHfW6ldHnvckBCe3OjeR?=MYW1cW0>Ml33OIg>MkHCbY5kemWjc3XzJGhNKHKnbHXhd4U>M4f0XlI1PzF|NUi3
A549NIj3N2ZCeG:ydH;zbZMhSXO|YYm=NXPvRVJ5PW2PNEDHTJQ1QGh?MmDh[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>?MXOyOFcxPjNyMx?=
U2OSMUfBdI9xfG:|aYOgRZN{[Xl?NFjIWWMyOG2PMX:yOIg>NFjCXnNqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h?MXKyOFY{QTBzMx?=
Saos-2NX20Oo85SXCxcITvd4l{KEG|c3H5MYWxNI1ONVi0fWdjOjSqM4DsfIlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>?NXL0ZW5IOjR4M{mwNVM>
A549M1LJNmFxd3C2b4Ppd{BCe3OjeR?=NETFcY4yOG2PMl\vOFhpNV;jN5Bx[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?=MXWyOFYzPjd{Mh?=
HCT116 NGP3clZCeG:ydH;zbZMhSXO|YYm=NIrKeGQ2dU1?NHHocnQzPGh?NEPzRVZmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6=NFT5Ro8zPDZ{NkWyNi=>
HGC-27Mni0SpVv[3Srb36gRZN{[Xl?MVGxNI1OM{nhU|FpNF;5TotqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhdG:|czDifUBTSURyMEGgc5IhVUtvMkKwOi=>NGq4UnQzPDRzNkO0PS=>
U2OS MXjGeY5kfGmxbjDBd5NigQ>?NWDHSIpvOC53L{HtUS=>NUK3fpYzPDiqMle3bY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M>NHj1OIozPDN3OEO0Ni=>
MG-63NWD6elRRTnWwY4Tpc44hSXO|YYm=MVGwMlUwOW2PMWq0PIg>M4m0SYlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{M2CwO|I1OzV6M{Sy
MG-63NWfkNlN1SXCxcITvd4l{KEG|c3H5M3PWTlAvPS9zbV2=NGjJ[3Y{Omh?M1HReIVvcGGwY3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO=NF\EUJUzPDN3OEO0Ni=>
MG-63MYTBdI9xfG:|aYOgRZN{[Xl?MVexNI1OMVyxNog>MmDm[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM>MXWyOFM2QDNyMR?=
NTUB1NXfqc5o4SXCxcITvd4l{KEG|c3H5MUm1cW0>NXjuS411OS53aB?=MUDwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM>MXGyOFM1QTF5Nh?=
T24MW\BdI9xfG:|aYOgRZN{[Xl?NIjPc2M2dU1?MmD1NU42cA>?NX;INIJVeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m|NHW1ZXUzPDN2OUG3Oi=>
SGC-7901 MX7BdI9xfG:|aYOgRZN{[Xl?MYSycW0>MXKxbC=>NEnSSVRqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?=NF\iWo8zPDN{MUO0NC=>
SMMC-7721NGDGTmpCeG:ydH;zbZMhSXO|YYm=M4LSSlJuVQ>?NWLO[2xIOWh?MYHpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>?NHnObZczPDN{MUO0NC=>
ECSCs MkmxRZBweHSxc3nzJGF{e2G7MlzENVBuVQ>?NV7Sb25{PGh?NGLQWZll\WO{ZXHz[ZMhemGyYX35Z4lvNXS{ZXH0[YQh[XCxcITvd4l{M4rsO|I1OzF7MUC5
MCF-7 NHztWVZHfW6ldHnvckBCe3OjeR?=NYfRbXZxOTCvTR?=NFPwTFEzPGh?MnTYbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IHPo[Y1wfGincnHwfUBlenWpcx?=MoKxNlQ{OTV3N{i=
UOK257NVLCZ3hISXCxcITvd4l{KEG|c3H5NVK0OWdmPW2PNUDYXnNnO2h?NXLuT49i\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?=MXyyOFMxPTZyNB?=
ACHN-5968MVHBdI9xfG:|aYOgRZN{[Xl?MVm1cW0>NXnxcXkyO2h?M4DTfoVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB?NVrrRWdwOjR|MEW2NFQ>
Huh7MV;BdI9xfG:|aYOgRZN{[Xl?NH6weI4zdU1?MUmxNog>NHvSXoJFVVORM2joW4lvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYToNFmzNY8zPDJ7N{OwNC=>
Hep3BM1rL[GFxd3C2b4Ppd{BCe3OjeR?=MnLhNo1OMlO3NVJpNH;ieYtFVVORMoL2bY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi=NX7sWGpUOjR{OUezNFA>
RKONHnIV29HfW6ldHnvckBCe3OjeR?=MkLmNo1OMlT3NYg>MnLPSG1UVw>?MWTlcohidmOnczDj[YxtKGSnYYToJIJ6KGenbHThcoFugWOrbh?=M1nVV|I1OjlzN{e3
HepG2 E47M1LJNmZ2dmO2aX;uJGF{e2G7Mn3sNk42dU1?NWe2fZFjPDiqM1zXSolv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES=NVPocZFXOjR{N{O3N|g>
LoVo MYXBdI9xfG:|aYOgRZN{[Xl?NGPudow2dU1?M{fzT|Q5cA>?M1TDfIVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5?NWC2V3RnOjR{MEG4NVI>
WiDrNWXsN3NwTnWwY4Tpc44hSXO|YYm=MYSxNI1OM3f6[VFpMmfRbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9vMkjkNlQyQTB2OEm=
H1299 NUXQRYM6TnWwY4Tpc44hSXO|YYm=NG\aUXcyOG2PNYHtfXJ2PGh?M2nFTYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRpM1vRWVI1OTd|MkC4
H460NF7sSWFHfW6ldHnvckBCe3OjeR?=NEXBSIEyOG2PM4L4OVRpNWXNcplGcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh?M3jacVI1OTd|MkC4
A549M{X1Z2Z2dmO2aX;uJGF{e2G7M{j4S|ExdU1?NWfZfpV{PGh?NUHVNHg6cW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36=M2roSVI1OTR{N{O1
Hep3BNUnVNWJnSXCxcITvd4l{KEG|c3H5NETZUJg2dU1?M{XjWFI1cA>?NIXNeotifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM>MUCyOFA3PjZ7Mx?=
SMMC-7721MnP5RZBweHSxc3nzJGF{e2G7MknKOY1OMXiyOIg>MnHQZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nzMn7UNlQxPjZ4OUO=
HO8910MVfBdI9xfG:|aYOgRZN{[Xl?NYfvUW5COTCvTR?=M{\CVVEzcA>?MmHE[Y5p[W6lZYOgRlE6NWmwZIXj[YQh[XCxcITvd4k>MWCyN|k5OzZzMB?=
MCF7M2fZcGZ2dmO2aX;uJGF{e2G7NY\zOHhoPW2PNFrL[IQzPGh?NXHTUlBicW6lcnXhd4V{KEO3TzDpcoR2[2WmIHPlcIwh\GWjdHi=NEnpN2UzOzl4Mk[yPS=>
HONE-1 M3;FWGZ2dmO2aX;uJGF{e2G7NF75VVM2dU1?NHXESW8ycA>?MWfy[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36=M1H4XFI{QDl{M{W4
HeLaNVjnUnR6TnWwY4Tpc44hSXO|YYm=MUexNI1OMU[ybC=>NYnI[mE2e3WycILld5NmeyCOQ{OgTWkh\XiycnXzd4l{d25?NITleZAzOzh4NEezPC=>
HepG2MUPGeY5kfGmxbjDBd5NigQ>?NHTpVmkyOG2PMXKyOIg>MVzpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?=NXTySJNYOjN6MUewOFA>
SH-SY5YNVPn[3NoTnWwY4Tpc44hSXO|YYm=MmHvNY1ONIK3WVEzPGh?NIXuVmpqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG9EWA>?NYPrNI9rOjN5NEOxOFg>
SH-SY5YNFfUSldCeG:ydH;zbZMhSXO|YYm=M1\HSFVuVQ>?MnO2NYg>Mk\KZYJwdGm|aHXzJINmdGG|dILvcEBv\XW{b4Dyc5Rm[3SrdnWg[YZn\WO2MUCyN|YyQTN7NR?=
PC12 M4[wemZ2dmO2aX;uJGF{e2G7NFzYN2syOG2PNFv1XoUzPGh?MnzVe4F1\XJ?NHfBN|jDqGmwaHnibZR{KGOqeX3veJJ6eHOrbj3sbYtmKHC{b4TlZZNwdWGuIHHjeIl3cXS7Lh?=NW\5eIR{OjN4MEO5O|k>
OV2008M4LkRWFxd3C2b4Ppd{BCe3OjeR?=MkSwOY1ONVHCbo13OjSqNWnmNVBG[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO=M2fYTlI{PTl{Mkix
A2780MmqwRZBweHSxc3nzJGF{e2G7MmjsOY1OMmfvNlRpMnPKZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN?NYHZdVVKOjN3OUKyPFE>
Saos-2 M4HFdmFxd3C2b4Ppd{BCe3OjeR?=MnTXNY1OM3LWNlk3cA>?MnH5bY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i=MmD2NlM2PjNzN{G=
1321N1NYXGUFl[S3m2b4TvfIlkcXS7IFHzd4F6NYq0[mdDPW2PMUWyOIg>NX;QZ2s6eHKxdHXjeJMh[2WubDDh[4FqdnO2IGDDUk1qdmS3Y3XkJJRwgGmlaYT5NXLZN5E5OjN3MkWyOlU>
SH-SY5YNXL1eFJLS3m2b4TvfIlkcXS7IFHzd4F6NH;NeXI2dU1?MUWyOIg>MWPpcoNz\WG|ZYOgVGNPKHSxeHnjbZR6MWCyN|UzPTJ4NR?=
HT-29 M4j3eWZ2dmO2aX;uJGF{e2G7MVmxcW0>NVHXOINOPDhxOU\oM3;wUolvcGmkaYTzJGFOWEtiaX7keYNmeyCjdYTvdIhi\2mlIHPlcIwh\GWjdHi=MoXUNlM2ODh{N{K=
OR6NX;rZXFZTnWwY4Tpc44hSXO|YYm=NIq5bGkyOG2PMYK3Nog>MYfzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{NIO3N4kzOzN7NUi3OS=>
Hela MW\GeY5kfGmxbjDBd5NigQ>?NFvkTlE2dU1?NH;KWJIzPGh?MlL2bY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=>NUD0WpRsOjN|OUW2O|k>
MCF-7 NIDmXWJHfW6ldHnvckBCe3OjeR?=MlG5OY1ONU\OXIF5OjSqMXnpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5M1Xm[VI{Ozl3Nke5
HUVECsMX\GeY5kfGmxbjDBd5NigQ>?NYLEZWEyO22PNUjk[VVQOjSqNEjrRZZjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7MnPTNlM{PTh7Mki=
T24NGfZZ2JHfW6ldHnvckBCe3OjeR?=NFW4WGQyOG2PMkWwNYg>M4K5OZJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS=Mo\LNlM{PTRyOEC=
U251MG MVPGeY5kfGmxbjDBd5NigQ>?NYnTbpBrO22PM2f2clFpNFXVeW5{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44>NUTKSmpwOjN|M{i2NVg>
GTL-16 MVTBdI9xfG:|aYOgRZN{[Xl?Mn[xOY1ONGmwNGozPGh?Mn;wdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO=NH32fVIzOzNzM{S5NC=>
T-47DNFnY[IxHfW6ldHnvckBCe3OjeR?=MXuxNI1OMojFNog>MmqwbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN?NEnmS|IzOzNyMECyOi=>
PaCa44MnTyRZBweHSxc3nzJGF{e2G7NGqzOXEzNjWvTR?=M1e0O|FpM2T4bZJm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nzMY[yN|EzPDFzMh?=
MDA-MB231MmDRSpVv[3Srb36gRZN{[Xl?NF;jN2g2dU1?MV6xbC=>NIHxcoNqdmO{ZXHz[ZMhemW|dnXyZZRzd2xvbXXkbYF1\WRiY3HzdIF{\SCjY4TpeoF1cW:wIHHu[EBk\WyuIHTlZZRpNF31foIzOzB6OEi1NC=>
HeLaMX;BdI9xfG:|aYOgRZN{[Xl?Mk\iNVBuVQ>?MWGybC=>MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSvZX70JJdqfGhiUFXJNHrtVnUzOzByMEGzOS=>
SK-HEP-1NYjtcnc2SXCxcITvd4l{KEG|c3H5MVyxNI1OMmLYNYg>NU\DeFB2eHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>?M1;iOlIzQDV6NkS5
HepG2MUfBdI9xfG:|aYOgRZN{[Xl?MnfmN41OM4nMclVpNXy3[Gt5emWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>?NHzHW|IzOjh|NkW5OS=>
MCF-7 M4fM[2Z2dmO2aX;uJGF{e2G7MmLJNo1OM2\wdFI1cA>?NW\WPIl4cW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=>NHfLO2kzPDl5ME[3Oi=>
MDA-MB-231NVfwSVN1TnWwY4Tpc44hSXO|YYm=MnjMNo1OMkH5NlRpNFPsNFhqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMgNX\TcpdmOjR7N{C2O|Y>
MCF-7 MX\GeY5kfGmxbjDBd5NigQ>?M3jmW|JuVQ>?MnTCOFhpMWPwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg>NX\QO2RROjR7N{C2O|Y>
MDA-MB-231MVHGeY5kfGmxbjDBd5NigQ>?MmHkNo1ONIn6dlc1QGh?MkXOdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRpNEnSV2czPDl5ME[3Oi=>
PANC-1 MnG0RZBweHSxc3nzJGF{e2G7M3LrT|FuVQ>?M2fhOlQ5cA>?M4[wWmROW09?NY\ZeGVy\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N?Mo\NNlQ5PDJzNUi=
MDA-MB 231NF\xfHJCeG:ydH;zbZMhSXO|YYm=MnXhOY1OMl;2NE42cA>?M2ntdo1w\HWuYYTld{BVd2OxbXnuxs7DqGmwZIXj[YQh[XCxcITvd4l{M3PmVFI1QDNyN{ix
Microglia NHjCWVlCeG:ydH;zbZMhSXO|YYm=NInZSm42dU1?MkfVNlRpM3rKN4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NI\SbWgzPDhzOE[wNS=>
A2780cpMnyxRZBweHSxc3nzJGF{e2G7M1;QfFIvPW2PMnTMNYg>NHraUYxl\Eh{Tx?=MonP[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>MWWyOFgyPzl2Nh?=
HepG2NV31eHRVTnWwY4Tpc44hSXO|YYm=NV7ic4x1PW2PNEXUb4E1cA>?M{XaSolv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?=NYLITYJ[OjR5MUO1PFc>
U2OSMn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfIOnIyOG2PNVPUcFA4OjSqMYLpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g>M4TLN|I1PjN7MEGz
HCT116NF3uWG5CeG:ydH;zbZMhSXO|YYm=NVO5SJpqPW2PMVSyOIg>NIHzVI5FVVORNUDhcVVS\W6qYX7j[ZMh[XCrZ3XubY4ucW6mdXPl[EBk\WyuIHTlZZRpM4HxclI1PjJ4NUKy
MCF-7 M4\BOGFxd3C2b4Ppd{BCe3OjeR?=NHj0clQxNjGvTR?=NGGxV|Q3cA>?M3fxUoVvcGGwY3XzJJNqenSrbn;sMYlv\HWlZXSgZZBweHSxc3nzMnL2NlI4PTF7OEm=
PC-3 MWTBdI9xfG:|aYOgRZN{[Xl?M{LLd|JuVQ>?MUmybC=>NGfwOItqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?=Ml;wNlI4PDV3OEC=
U251 MkXnRZBweHSxc3nzJGF{e2G7M4TxUFVuVQ>?NYeycoV[OjSqNXnObFhucW6lcnXhd4V{KFNzLXnu[JVk\WRiY3XscEBl\WG2aB?=M2HnTVIzPTd7N{i4
HeLa M2LZeWFxd3C2b4Ppd{BCe3OjeR?=MnTsOY1ONEPRWFMzPGh?M3XoTIlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=>M3\Vb|IzPTR3MUK4
A549NGnWXldHfW6ldHnvckBCe3OjeR?=NUTBW2d5OC5zbV2=MXiyOIg>NUWzWFlNe3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>?NF65UI8zOjR4Nkm2NC=>
pDCsMmDnSpVv[3Srb36gRZN{[Xl?NFruS4QyOG2PM{LTb|AvPWh?MX9CpJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDJSm4u|rFiYomgd5NTVkF2MB?=Mo\ONlI{QTZ3OUm=
BGC-823MVrGeY5kfGmxbjDBd5NigQ>?M3fJbVVuVQ>?M{fzV|JpM1zjXolvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM>M4nLblIzOzJ{MUWy
U937NVG4NW1FTnWwY4Tpc44hSXO|YYm=Ml7jNo1OMXSxNog>MUXk[YNz\WG|ZYOgeIhmKGG3dH;wbIFogSC{YYTpc:KhNYm0eXFwOjJzNUWxOVA>
Marc-145MVvGeY5kfGmxbjDBd5NigQ>?MUS1cW0>MoTmNVIwOjRxM{\oNY\Mco9TemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uNGTTcpczOjFzOUmwNC=>
HBx MlnERZBweHSxc3nzJGF{e2G7MU[xNI1OMnHXOFhpMXfEUXNQMlLFbY5kemWjc3XzJINmdGxiZHXheIg>NYW3eoJUOjJyMkCwO|g>
MCF-7NV\BOJNPTnWwY4Tpc44hSXO|YYm=NXXDOVlnOTCvTR?=Mln2OFhpMYTicI9kc3NiYYX0c5Bp[We7IHnu[JVk\WRiYomgZo9zfGW8b33pZi=>NV3UdHpPOjF7M{G5N|c>
RMPI8226 M3;WW2Z2dmO2aX;uJGF{e2G7MYS1cW0>MnjPNYg>NIjoRpN{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:wM17LclIyQTF3NkKw
PC12/TetOnMWXGeY5kfGmxbjDBd5NigQ>?NYTPNGgzOC5zL{HtUS=>NUDoflVrOTiqMki4cIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB?MUmyNVkxPjZ3OR?=
HeLa M2fGWGN6fG:2b4jpZ4l1gSCDc4PhfS=>MnOyNo1ONFWzNXczPGh?MXHpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6=MnjmNlE5PzV|OEW=
JurkatM2PkXmZ2dmO2aX;uJGF{e2G7MlXXNVBuVQ>?MoezNYg>M3Xs[IRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=NWrFd5ZMOjF6NkSwN|c>
K562Mn;QSpVv[3Srb36gRZN{[Xl?NH3YV4QyOG2PNEfQelEycA>?M3;O[IRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=MUGyNVg3PDB|Nx?=
Nara-HNGHJe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYC1cW0>NIm2TXc1QGh?M37yNoVvcGGwY3XzJJRmdXOrcn;sbY12e22nZHnheIVlKHO3cIDy[ZN{cW:wIH;mJG5iemFvSDDj[YxtKHC{b3zp[oVz[XSrb36=MXmyNVgxPTB|Mx?=
HUVECsNX3Z[|dtTnWwY4Tpc44hSXO|YYm=MVKxNI1OMo[0NE42cA>?NGTZWIhl\WO{ZXHz[ZMhfGinIFHHSU1DW0GrbnT1Z4VlKGG3dH;wbIFogSCuZY\lNF3SOmMzOTR4OEW5Ni=>
HepG2NETmOHFCeG:ydH;zbZMhSXO|YYm=NXHkT2hzOm2PNWfzfWlDOWh?NFzicG5mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRpNGLuVpUzOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [4]

Protein degradation assay HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.

Cell Assay: [2]

Cell lines HeLa cell line
Concentrations 1-10 mM
Incubation Time 24, 48 or 72 hours
Method Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.

Animal Study: [5]

Animal Models Adult male Sprague–Dawley rats weighing 300-350 g
Formulation Saline
Dosages 400 nM
Administration Intracerebral ventricular

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Miller S, et al. Autophagy. 2010, 6(6), 805-807.

[2] Hou H, et al. PLoS One. 2012, 7(4), e35665.

view more

Chemical Information

Download 3-Methyladenine (3-MA) SDF
Molecular Weight (MW) 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms NSC 66389
Solubility (25°C) * In vitro DMSO 3 mg/mL warming (20.11 mM)
Water 20 mg/mL warming (134.09 mM)
Ethanol 4 mg/mL (26.81 mM)
In vivo water 20mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 3-methyl-3H-purin-6-amine

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us